| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/02/2023 | 52.46% | Morgan Stanley | $42 → $38 | Maintains | Overweight |
| 09/28/2023 | 32.4% | Piper Sandler | → $33 | Initiates Coverage On | → Overweight |
| 08/07/2023 | 0.3% | Mizuho | $29 → $25 | Maintains | Neutral |
| 08/03/2023 | 68.51% | Morgan Stanley | $46 → $42 | Maintains | Overweight |
| 08/03/2023 | 24.37% | B of A Securities | $36 → $31 | Downgrades | Buy → Neutral |
| 08/03/2023 | 64.49% | HC Wainwright & Co. | $45 → $41 | Maintains | Buy |
| 05/23/2023 | 20.36% | Goldman Sachs | $31 → $30 | Maintains | Neutral |
| 05/08/2023 | 16.35% | Mizuho | $26 → $29 | Maintains | Neutral |
| 05/04/2023 | 20.36% | Wells Fargo | → $30 | Upgrades | Equal-Weight → Overweight |
| 04/10/2023 | — | TD Cowen | Initiates Coverage On | → Outperform | |
| 04/03/2023 | 80.54% | HC Wainwright & Co. | → $45 | Reiterates | → Buy |
| 03/17/2023 | 16.35% | JP Morgan | $40 → $29 | Downgrades | Overweight → Neutral |
| 03/16/2023 | -11.74% | Berenberg | → $22 | Reinstates | → Hold |
| 03/09/2023 | 4.31% | Mizuho | $28 → $26 | Maintains | Neutral |
| 02/23/2023 | 60.48% | Morgan Stanley | $50 → $40 | Maintains | Overweight |
| 02/23/2023 | 80.54% | HC Wainwright & Co. | $48 → $45 | Maintains | Buy |
| 02/23/2023 | 20.36% | Wells Fargo | $38 → $30 | Downgrades | Overweight → Equal-Weight |
| 02/22/2023 | 24.37% | Goldman Sachs | $28 → $31 | Maintains | Neutral |
| 12/06/2022 | 60.48% | JP Morgan | $49 → $40 | Maintains | Overweight |
| 11/10/2022 | 12.34% | Mizuho | $32 → $28 | Maintains | Neutral |
| 11/09/2022 | 92.58% | HC Wainwright & Co. | $50 → $48 | Maintains | Buy |
| 11/01/2022 | 60.48% | Loop Capital | → $40 | Initiates Coverage On | → Buy |
| 10/20/2022 | 56.47% | B of A Securities | → $39 | Initiates Coverage On | → Buy |
| 09/29/2022 | 64.49% | Cantor Fitzgerald | → $41 | Initiates Coverage On | → Overweight |
| 09/26/2022 | 52.46% | Wells Fargo | → $38 | Initiates Coverage On | → Overweight |
| 09/21/2022 | 12.34% | Goldman Sachs | $24 → $28 | Maintains | Neutral |
| 09/13/2022 | — | Evercore ISI Group | Initiates Coverage On | → Outperform | |
| 08/23/2022 | 28.39% | Mizuho | $27 → $32 | Maintains | Neutral |
| 08/22/2022 | 100.6% | Morgan Stanley | $39 → $50 | Maintains | Overweight |
| 08/09/2022 | 116.65% | Stifel | $50 → $54 | Maintains | Buy |
| 08/03/2022 | 8.32% | Mizuho | $30 → $27 | Maintains | Neutral |
| 07/07/2022 | 20.36% | Mizuho | → $30 | Initiates Coverage On | → Neutral |
| 05/24/2022 | -19.76% | Goldman Sachs | $28 → $20 | Maintains | Neutral |
| 02/15/2022 | 8.32% | Goldman Sachs | → $27 | Initiates Coverage On | → Neutral |
| 01/05/2022 | 100.6% | JP Morgan | → $50 | Initiates Coverage On | → Overweight |
| 12/16/2021 | 100.6% | HC Wainwright & Co. | → $50 | Initiates Coverage On | → Buy |
| 09/07/2021 | 56.47% | Morgan Stanley | $27 → $39 | Maintains | Overweight |
| 06/18/2021 | 8.32% | Morgan Stanley | → $27 | Initiates Coverage On | → Overweight |
| 12/10/2020 | -3.71% | Goldman Sachs | → $24 | Initiates Coverage On | → Buy |
| 11/23/2020 | -27.78% | Jefferies | → $18 | Initiates Coverage On | → Buy |
| 11/09/2020 | -31.8% | Stifel | → $17 | Initiates Coverage On | → Buy |
What is the target price for Cerevel Therapeutics Hldg (CERE)?
The latest price target for Cerevel Therapeutics Hldg (NASDAQ: CERE) was reported by Morgan Stanley on November 2, 2023. The analyst firm set a price target for $38.00 expecting CERE to rise to within 12 months (a possible 52.46% upside). 21 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cerevel Therapeutics Hldg (CERE)?
The latest analyst rating for Cerevel Therapeutics Hldg (NASDAQ: CERE) was provided by Morgan Stanley, and Cerevel Therapeutics Hldg maintained their overweight rating.
When is the next analyst rating going to be posted or updated for Cerevel Therapeutics Hldg (CERE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cerevel Therapeutics Hldg, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cerevel Therapeutics Hldg was filed on November 2, 2023 so you should expect the next rating to be made available sometime around November 2, 2024.
Is the Analyst Rating Cerevel Therapeutics Hldg (CERE) correct?
While ratings are subjective and will change, the latest Cerevel Therapeutics Hldg (CERE) rating was a maintained with a price target of $42.00 to $38.00. The current price Cerevel Therapeutics Hldg (CERE) is trading at is $24.93, which is out of the analyst's predicted range.